Indie Semiconductor, Inc. — Form 8-K Summary
Business context and reporting period
Filed under Section 13 or 15(d) of the Exchange Act, with an earliest reported event date of August 27, 2021 and signature date of September 2, 2021. The filing announces a proposed acquisition of TeraXion, Inc., a Canadian company, by indie’s wholly owned Canadian subsidiary.
Transaction and key financial terms
- Aggregate purchase price: CAD $200 million, payable 50% in cash and 50% in indie Class A common stock valued at US$10 per share.
- Based on the stated August 31, 2021 exchange rate, the estimated purchase price was approximately US$158.5 million, consisting of approximately US$79.3 million in cash and 7,926,000 shares.
- The purchase price remains subject to working-capital and other adjustments, which indie anticipated would reduce the stated amounts.
- Indie expects to issue no more than approximately 8,000,000 Class A shares at closing, although the final amount will depend on adjustments, exchange rates and TeraXion option exercises.
- No revenue, profit, cash-flow, margin, debt or liquidity figures are provided in this filing.
Material changes versus the prior comparable period
The filing does not provide comparative financial statements or period-over-period operating results. The material development is the entry into a definitive agreement to acquire TeraXion and the planned issuance of cash and equity consideration.
Guidance, outlook, risks and unusual items
- The transaction was approved by both companies’ boards and was expected to close in the fourth quarter of 2021, subject to regulatory approval and customary closing conditions.
- The acquisition constitutes a liquidity event under TeraXion’s option plan, accelerating vesting of all outstanding options.
- Option holders may exercise their options or enter into an option settlement arrangement. Settlement consideration is generally expected to be 50% cash and 50% in replacement or assumed options exercisable for indie Class A common stock.
- The shares issued to TeraXion stockholders are expected to be issued under Securities Act Section 4(a)(2) and Regulation S exemptions. Indie agreed to file a Form S-1 registration statement for resale of those shares.
- Key risks include regulatory review, failure to satisfy closing conditions, foreign-exchange movements, changes in indie’s share price, integration challenges, failure to realize anticipated benefits or synergies, and technological or product-development risks.
- The transaction may result in material cash usage and dilution to existing indie stockholders, but the filing does not provide post-transaction liquidity projections or an estimate of total dilution including replacement options.
Important facts for investors to verify
- Whether the acquisition closed as expected in the fourth quarter of 2021 and whether all closing conditions and regulatory approvals were satisfied.
- The final purchase price after working-capital and other adjustments.
- The final cash consideration, exchange rate used and number of Class A shares issued.
- The number and treatment of TeraXion options, including options exercised, settled or replaced with indie options.
- Indie’s available cash, financing sources and liquidity after funding the cash portion of the acquisition.
- The filing’s referenced Purchase Agreement, Option Settlement Agreement, subsequent Form S-1 and later periodic reports for final transaction terms and integration results.